FDA official discusses UniQure gene remedy for Huntington’s illness

UniQure must run one other research to show that its gene remedy “truly helps individuals with Huntington’s illness,” a senior U.S. Meals and Drug Administration official mentioned on a name with reporters Thursday.

The official, who requested anonymity earlier than discussing delicate data, confirmed the company has requested the corporate to run a placebo managed trial of its remedy, which is run straight into the mind. UniQure has mentioned that kind of research is not moral as a result of it will require placing individuals below basic anesthesia for hours, a characterization the official disputed.

“So what is absolutely happening? UniQure is the most recent firm to make a failed remedy for Huntington’s sufferers,” the official mentioned. “They possible acknowledge or perceive at some deep degree that their trial failed years in the past, and as a substitute of doing the appropriate factor and operating the right scientific research, UniQure is performing a distorted or manipulated comparability within the thoughts of FDA.”

The feedback mark the most recent growth in a messy public spat between UniQure and the FDA, and as the company comes below fireplace for numerous current drug approval software rejections, together with some the place firms have accused it of going again on earlier steerage. FDA Commissioner Marty Makary in an interview with CNBC’s Becky Fast final week seemingly criticized UniQure’s gene remedy for Huntington’s illness. Makary did not title UniQure however described its remedy.

UniQure then accused the FDA of reversing its stance that the corporate’s scientific trial knowledge can be enough to hunt approval. UniQure’s research used an outdoor database to measure how sufferers with Huntington’s illness may decline with out remedy, often called an exterior management. UniQure has mentioned it would not be possible to run a real randomized, double-blind placebo-controlled research, thought-about the gold customary, as a result of it would not be moral to make individuals endure a sham hours-long mind surgical procedure.

The FDA official mentioned the company “by no means agreed to simply accept this distorted comparability” and the FDA “by no means makes such assurances.” As a substitute, the “FDA will at all times say, ‘Effectively, we have now to see the info once we get it.'”

UniQure in a press release mentioned it is “assured within the energy of the info we have now submitted to the FDA” and it shares “the administration’s purpose of creating significant therapies for sufferers affected by uncommon ailments.”

“The current statements made by nameless FDA sources to the press have been extremely irregular, unprecedented, and are incomplete or totally incorrect,” the corporate mentioned. “We don’t consider they replicate a good and trustworthy studying of the paperwork we have now submitted or these we have now acquired from the company.”

The corporate’s inventory rose 18% on Thursday and has fallen 56% this 12 months as of Thursday’s shut.